Deloitte Report: Biopharma R&D Trends Show Rebound in Returns Amidst Ongoing Pressures

Deloitte's 14th annual report on pharmaceutical innovation analyzed R&D trends for 20 leading biopharma companies in 2023, revealing a rebound in average returns to 4.1%, up from a low of 1.2% in 2022. However, R&D executives cited ongoing pressures from regulatory changes, loss of exclusivity, and rising complexity. Deloitte experts emphasize the need for transformational change to drive consistent returns, highlighting potential value opportunities of $5 to 7 billion. They stress continued investment in early R&D and efficient execution to navigate challenges and foster innovation in the industry.